Tumor Registry of Advanced Renal Cell Carcinoma

Completed

• Conditions: Renal Cell Carcinoma

• Registration Number: NCT00610012
• Lead Sponsor: iOMEDICO AG

Brief Summary

The purpose of this registry is to record information of therapy reality of metastatic or locally advanced Renal Cell Carcinoma by office-based medical oncologists in Germany.

Detailed Description

The RCC Registry is a prospective, longitudinal, nation wide cohort study that collects data on the treatment reality of patients with mRCC. At inclusion, data in patient characteristics, comorbidities, tumor characteristics, and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented. Patients are followed until death or for a maximum of 3 years.

Study Timeline

• Study Start: 2007-12
• Study First Submitted: 2008-01-25
• Study First Submitted QC: 2008-02-06
• Study First Posted: 2008-02-07
• Status Verified: 2020-05
• Primary Completion: 2020-05-15
• Study Completion: 2020-05-15
• Last Update Submitted: 2020-05-26
• Last Update Posted: 2020-05-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1500

Inclusion Criteria

• Patients with metastatic or locally advanced Renal Cell Carcinoma requiring therapy
• Start of first palliative therapy within 1 year before enrollment of patient to registry; since enrollment of 1000 Patients: start of first palliative therapy within 4 weeks before enrollment

Exclusion Criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Documentation of therapies	9 years, 3 years per patient

Secondary Outcome Measures

Name	Time	Method
Documentation of response rate and adverse reactions; development of a numeric prognostic score	9 years

Trial Locations

Locations (1)

iOMEDICO; 🇩🇪 Freiburg, Germany